Molecular Detection Inc. (MDI), a US-based company with offices in Wayne, PA, Tunbridge Wells, UK and Jerusalem, Israel, is developing and commercializing sample-to-answer Detect-Ready molecular diagnostic tests for the detection of infectious diseases. The company's first product, a ready-to-use, rapid detection panel for hospital-based MRSA screening, is commercially available in the EU, Australia and the Middle East.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/16/12 | $1,900,000 | Series B |
Elm Spring Holdings Mid-Atlantic Angel Group Robin Hood Ventures | undisclosed |
